Optometry Educational Dinner | Updates in Primary Eyecare | Ocular Surgery

The Optometry Educational Dinner Updates in Primary Eyecare | Ocular Surgery is brought to you by The Layton Vision Foundation (LVF) and the LVF Ophthalmology Research Centre.  

It is common for patients to generally present to their Optometrist with any post operative complications following routine ophthalmic surgery. This education presentation provides an overview of complications that are common to all types of ocular surgery and provides the framework of diagnosis and management regardless of the type of surgery performed. Addressing the following key points:

• Pre-operative and post-operative care
• Complications and management
• The importance of collaborative care and communication between ophthalmologists and optometrists to achieve the best outcomes for patients.
• Future developments in eye surgery

This event will be accredited by Optometry Australia for Continuing Professional Development (CPD) points, including the interactive points. In addition to this, you will receive a Certificate of Attendance on the evening, with the Topic, a short description of presentation for your reference and record to accumulate towards your CPD Points.

Please note the Registration Desk will be open from 6.30pm with official proceedings set to commence at 7pm.  We plan to wrap up and close by 9pm.

Our Presenter - Professor Christopher Layton:

Professor Christopher Layton (Dr Chris) is a private Clinical Ophthalmologist, Rhodes Scholar and a national leader in innovative ophthalmology. His expertise is in macular disease, lens surgery and minimally invasive glaucoma interventions.

He completed optometry at QUT, ophthalmology in Queensland, Oxford and London, subspecialty training in retinal disease at the Royal Brisbane Hospital and holds a PhD in diabetic retinopathy from Oxford University. Professor Layton is a Rhodes Scholar and founding director of the LVF Ophthalmology Research Centre. He is also CEO of Ocugene, a Queensland based biotech start-up which is commercialising his gene therapy technology targeting macular degeneration, uveitis and choroidal melanoma.

Register today so you don't miss out on your place, as it is limited to 60 places.  If you have any questions or query, please contact Janelle Bostock on E:j.bostock@laytonfoundation.org.au